972 results on '"Voest, Emile E."'
Search Results
2. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
3. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
4. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
5. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
6. Functional precision oncology using patient-derived assays: bridging genotype and phenotype
7. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
8. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
9. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
10. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
11. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
12. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity
13. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
14. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
15. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)
16. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
17. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
18. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
19. Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
20. Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
21. Data from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
22. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
23. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
24. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
25. Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer
26. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
27. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system
28. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
29. Facilitating a culture of responsible and effective sharing of cancer genome data
30. Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics
31. Caring for patients with cancer in the COVID-19 era
32. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
33. Tumor organoid–T-cell coculture systems
34. Pan-cancer whole-genome analyses of metastatic solid tumours
35. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
36. When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward
37. Is It Our Duty To Hunt for Pathogenic Mutations?
38. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
39. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)
40. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
41. Supplementary Materials and Methods from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
42. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium
43. Supplementary Figures 1-11 from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
44. Table S3 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
45. Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
46. Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
47. Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
48. Data from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
49. Supplementary Figure 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
50. Supplementary Table 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.